People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. | — | Biotechnology | Series C | $115.5M | $2.4B | 2021 |
Peter Blume-Jensen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Blume-Jensen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Derek DiRocco | 1 | 7 |
| Sharon Shacham | 1 | 4 |
| Erick Gamelin | 1 | 2 |
| Kristina Masson | 1 | 1 |
| Marcin Czernik | 1 | 1 |
| Eric Devroe | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.